A Non-interventional, Prospective Study in Germany to Investigate the Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in a Patient Population With Isolated Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Sponsors Novo Nordisk
Most Recent Events
- 08 Nov 2022 Planned End Date changed from 30 Jun 2029 to 30 Jun 2031.
- 01 Jul 2019 Status changed from not yet recruiting to recruiting.
- 07 Jun 2019 New trial record